Lufax Holding Ltd vs Revvity Inc — how do they compare? Lufax Holding Ltd trades at $0.99 (market cap $982.89M), while Revvity Inc trades at $154.89 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 17.3× Lufax Holding Ltd's market cap, and Revvity Inc pays a 0.18% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lufax Holding Ltd for 13 Days and Revvity Inc for 12 Days on average.
| LU | RVTY | |
|---|---|---|
Market Cap | $982.89M | $16.98B |
Volume | 3,323,384 | 1,456,900 |
Sector | Financials | Health |
52-Week High | $3.93 | $157.36 |
52-Week Low | $0.95 | $82.26 |
Typical Hold Time | 13 Days | 12 Days |
Enterprise Value | $58.81B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Lufax (LU) trades at $0.986, up 0.47% on the day, but shows significant fundamental challenges with consecutive quarterly losses and declining revenue. The company recently completed a 10:1 reverse stock split and faces bearish technical signals despite some oversold RSI readings. Analyst sentiment remains predominantly bullish with 69% buy ratings, pointing to potential value in the depressed valuation multiples.
The investment case hinges on Lufax's deep value proposition trading at 0.07x book value, but requires successful navigation of regulatory headwinds and return to profitability. Key risks include persistent net losses, Chinese regulatory uncertainty, and declining top-line performance that could pressure the stock further despite strong institutional backing from parent company Ping An.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →